NasdaqGS:EPZM

Stock Analysis Report

Executive Summary

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.

Share Price & News

How has Epizyme's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.0%

EPZM

3.8%

US Biotechs

2.3%

US Market


1 Year Return

16.7%

EPZM

-10.0%

US Biotechs

5.6%

US Market

Return vs Industry: EPZM exceeded the US Biotechs industry which returned -10% over the past year.

Return vs Market: EPZM exceeded the US Market which returned 5.6% over the past year.


Shareholder returns

EPZMIndustryMarket
7 Day3.0%3.8%2.3%
30 Day-12.4%-2.8%-1.0%
90 Day-19.3%-2.6%-0.7%
1 Year16.7%16.7%-9.2%-10.0%7.9%5.6%
3 Year15.4%15.4%14.7%10.7%45.6%36.3%
5 Year-65.6%-65.6%2.2%-2.8%65.8%47.6%

Price Volatility Vs. Market

How volatile is Epizyme's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Epizyme undervalued compared to its fair value and its price relative to the market?

3.24x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate EPZM's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate EPZM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EPZM is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: EPZM is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate EPZM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EPZM is overvalued based on its PB Ratio (3.2x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Epizyme forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

38.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EPZM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EPZM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EPZM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EPZM's revenue (64.4% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: EPZM's revenue (64.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: EPZM is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Epizyme performed over the past 5 years?

-15.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: EPZM is unprofitable, and losses have increased over the past 5 years at a rate of -15.4% per year.

Accelerating Growth: Unable to compare EPZM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EPZM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: EPZM has a negative Return on Equity (-42.45%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: EPZM is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: EPZM is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Epizyme's financial position?


Financial Position Analysis

Short Term Liabilities: EPZM's short term assets ($358.4M) exceeds its short term liabilities ($33.9M)

Long Term Liabilities: EPZM's short term assets (358.4M) exceeds its long term liabilities (11.8M)


Debt to Equity History and Analysis

Debt Level: EPZM is debt free.

Reducing Debt: EPZM has not had any debt for past 5 years.


Balance Sheet

Inventory Level: EPZM has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if EPZM's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EPZM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: EPZM has sufficient cash runway for 2.210397 years if free cash flow continues to reduce at historical rates of -13.5% each year.


Next Steps

Dividend

What is Epizyme's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.0%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate EPZM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate EPZM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if EPZM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EPZM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EPZM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Epizyme's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Rob Bazemore (51yo)

4.1yrs

Tenure

US$3,650,871

Compensation

Mr. Robert B. Bazemore, Jr., also known as Bob, has been the Chief Executive Officer and President at Epizyme, Inc. since September 10, 2015 and serves as its Secretary. Mr. Bazemore served as the Chief Op ...


CEO Compensation Analysis

Compensation vs. Market: Rob's total compensation ($USD3.65M) is about average for companies of similar size in the US market ($USD2.69M).

Compensation vs Earnings: Rob's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

0.8yrs

Average Tenure

51.5yo

Average Age

Experienced Management: EPZM's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Age and Tenure

4.1yrs

Average Tenure

60yo

Average Age

Experienced Board: EPZM's board of directors are considered experienced (4.1 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$652,13428 Jun 19
New Enterprise Associates
EntityCompany
Shares52,473
Max PriceUS$12.43
SellUS$1,372,82526 Jun 19
New Enterprise Associates
EntityCompany
Shares104,944
Max PriceUS$13.31
SellUS$14,33914 Jun 19
Matthew Ros
EntityIndividual
Role
Senior Key Executive
Chief Strategy & Business Officer
Shares1,185
Max PriceUS$12.10

Ownership Breakdown


Management Team

  • Rob Bazemore (51yo)

    President

    • Tenure: 4.1yrs
    • Compensation: US$3.65m
  • H. Horvitz

    Co-Founder & Chairman of the Scientific Advisory Board

    • Tenure: 0yrs
  • John Weidenbruch (58yo)

    General Counsel

    • Tenure: 0yrs
  • Matt Ros (52yo)

    Chief Strategy & Business Officer

    • Tenure: 0.2yrs
    • Compensation: US$1.72m
  • Yi Zhang

    Scientific Co-Founder & Member of The Scientific Advisory Board

    • Tenure: 0yrs
  • Paolo Tombesi (55yo)

    Chief Financial Officer

    • Tenure: 0.2yrs
  • Shefali Agarwal (45yo)

    Chief Medical Officer

    • Tenure: 1.3yrs
    • Compensation: US$2.00m
  • Jason Fredette

    Vice President of Investor Relations

    • Tenure: 0yrs
  • Andrea Edwards

    Head of Human Resources & Organizational Development

    • Tenure: 0yrs
  • Joseph Beaulieu (38yo)

    Controller

    • Tenure: 0.8yrs

Board Members

  • George Daley

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Dave Mott (54yo)

    Independent Chairman

    • Tenure: 3.5yrs
    • Compensation: US$242.08k
  • Carl Goldfischer (60yo)

    Independent Director

    • Tenure: 10.1yrs
    • Compensation: US$198.92k
  • Chris Walsh (75yo)

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Rob Bazemore (51yo)

    President

    • Tenure: 4.1yrs
    • Compensation: US$3.65m
  • Bruce Chabner (78yo)

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • H. Horvitz

    Co-Founder & Chairman of the Scientific Advisory Board

    • Tenure: 0yrs
  • Ronald Evans

    Member of the Scientific Advisory Board

    • Tenure: 0yrs
  • Yi Zhang

    Scientific Co-Founder & Member of The Scientific Advisory Board

    • Tenure: 0yrs
  • Joel Huff

    Member of the Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Epizyme, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Epizyme, Inc.
  • Ticker: EPZM
  • Exchange: NasdaqGS
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$934.946m
  • Shares outstanding: 91.04m
  • Website: https://www.epizyme.com

Number of Employees


Location

  • Epizyme, Inc.
  • 400 Technology Square
  • 4th Floor
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EPZMNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2013
EPEDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2013

Biography

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The com ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 00:24
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.